Listed by the USPTO as THOMAS, TIMOTHY P
Tech Center 1600 • Art Units: 1611 1614 1628
This examiner grants 26% of resolved cases
Timothy P. Thomas presents a challenging environment in Art Unit 1611, with an allowance rate of only 26.3% across 913 resolved cases. This is a very low rate, indicating that the majority of applications do not reach a grant in Tech Center 1600. The median days to allowance is 1352, which means that even successful cases require a long and difficult prosecution path.
However, the interview lift of 38.0% is a critical metric for practitioners. This high value suggests that interviews are a vital tool for overcoming rejections and significantly improve the odds of an allowance compared to the 26.3% baseline. His caseload includes work for Vector Vitale Ip LLC, Remedy Pharmaceuticals Inc., and Danstar Ferment AG. These companies face a rigorous examination process in the pharmaceutical sector.
The firms Liang & Hennessey LLP, BakerHostetler, and Bayramoglu Law Offices LLC are the most frequent representatives in his profile. The 26.3% allowance rate and 38.0% interview lift highlight a clear strategy: written advocacy alone is often insufficient. With a median days to allowance of 1352, applicants must be prepared for a multi-year effort. Direct engagement with the examiner is the most effective way to navigate this difficult art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19191890 | LOW-SORBING GLYBURIDE FORMULATION AND METHODS | Final Rejection | REMEDY PHARMACEUTICALS, INC. |
| 17614267 | COMPOSITION AND METHOD FOR ENHANCING SPORE GERMINATION AND BIOLOGICAL EFFICACY | Non-Final OA | DANSTAR FERMENT AG |
| 18581659 | METHOD OF TREATING ALZHEIMER'S DISEASE | Non-Final OA | Vector Vitale IP LLC |
| 17064443 | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF OBESITY | Final Rejection | Vector Vitale IP LLC |
| 16310857 | SYNERGISTIC ANTIMICROBIAL COMBINATIONS CONTAINING QUATERNARY AMMONIUM BIOCIDE | Final Rejection | LONZA, LLC |
| 17921540 | SOLID AND LIQUISOLID FORMULATIONS OF CORALLOPYRONIN A | Final Rejection | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN |
| 17917608 | COMPOSITION COMPRISING RESVERATROL | Final Rejection | GALENUS G.H. AG |
| 17792863 | TOPICAL FORMULATION CONTAINING RAPAMYCIN | Final Rejection | NOBELPHARMA CO., LTD. |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | Final Rejection | SQUARE POWER LTD. |
| 17520763 | Photosensitive Dyes and Method of Using Said Dyes | Final Rejection | STRT LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy26.3% of resolved applications examined by Timothy P Thomas were allowed (913 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +38.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Timothy P Thomas took 1,352 days on average from filing to allowance.
Timothy P Thomas examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
